Net profit of Corona Remedies declined 8.19% to Rs 41.27 crore in the quarter ended December 2025 as against Rs 44.95 crore during the previous quarter ended December 2024. Sales rose 15.03% to Rs 342.42 crore in the quarter ended December 2025 as against Rs 297.69 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales342.42297.69 15 OPM %24.2923.32 - PBDT83.7667.97 23 PBT74.3158.28 28 NP41.2744.95 -8 Powered by Capital Market - Live News

Corona Remedies will hold a meeting of the Board of Directors of the Company on 2 February 2026.Powered by Capital Market - Live News

Corona Remedies will hold a meeting of the Board of Directors of the Company on 2 January 2026.Powered by Capital Market - Live News

The equity shares of Corona Remedies (Scrip Code: 544644) are listed effective 15 December 2025 and admitted to dealings on the Exchange in the list of ``B`` Group Securities. At 09:30 IST, the pre-open indicative price of the stock was at a premium of 4.61% to the issue price of Rs 1062. Powered by Capital Market - Live News